thymosin alpha 1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
== Further reading == Goldman, Lee (15 April 2001). "Key challenges confronting internal medicine in the early twenty-first century". The American Journal of Medicine. 110 (6): 463–470. doi:10.1016/S0002-9343(01)00649-0. PMID 11331058. Meltzer, David; Manning, WG; Morrison, J; Shah, MN; Jin, L; Guth, T; Levinson, W (Dec 3, 2002). "Effects of Physician Experience on Costs and Outcomes on an Academic General Medicine Service: Results of a Trial of Hospitalists". Annals of Internal Medicine. 137 (11): 866–74. doi:10.7326/0003-4819-137-11-200212030-00007. PMID 12458986. S2CID 31987327. Salerno, Stephen M; Landry, Francis J; Kaboli, Peter J (Feb 1, 2001). "Patient perceptions of the capabilities of internists: a multi-center survey". The American Journal of Medicine. 110 (2): 111–117. doi:10.1016/S0002-9343(00)00666-5. PMID 11165552. Sox, Harold C (Jun 15, 2001). "Supply, demand, and the workforce of internal medicine". The American Journal of Medicine. 110 (9): 745–749. doi:10.1016/S0002-9343(01)00756-2. PMID 11403763. Wetterneck, Tosha B.; Linzer, M; McMurray, JE; Douglas, J; Schwartz, MD; Bigby, J; Gerrity, MS; Pathman, DE; et al. (Mar 25, 2002). "Worklife and Satisfaction of General Internists". Archives of Internal Medicine. 162 (6): 649–56. doi:10.1001/archinte.162.6.649. PMID 11911718.
== Sample preparation == Sample preparation is one of the most critical steps in NanoSIMS analysis, particularly when analysing biological samples. Specific protocols should be developed for individual experiments in order to best preserve not only the structure of the sample but also the true spatial distribution and abundance of molecules within the sample. As the NanoSIMS operates under ultra high vacuum, the sample must be vacuum compatible (i.e., volatile free), flat, which reduces varying ionization trajectories, and conductive, which can be accomplished by sputter coating with Au, Pt, or C. Biological samples, such as cells or tissue, can be prepared with chemical fixation or cryo-fixation and embedded in a resin before sectioning into thin slices (100 nm - 1μm), and placed on silicon wafers or slides for analysis. Sample preparation for metallographic samples is generally much simpler but a very good metallographic polish is required to achieve a flat, scratch free surface.
Its main adverse effects are linked to infusion-site reactions which, even though mild to moderate, are responsible for early discontinuation. Levodopa-carbidopa microtablets (LC-5), marketed as Flexilev, are small dispersible low-dose tablets consisting of 5 mg levodopa and 1.25 carbidopa per tablet. The tablets are designed for frequent oral dosing throughout the day in order to maintain stable levodopa concentrations in the blood via fine granularity. Pharmacokinetic studies demonstrated the bioequivalence of LC-5 to standard levodopa/carbidopa tablets and showed that fractionated administration reduce the fluctuations of plasmatic levodopa while keeping high adherence, symptoms improvement and lower cost estimates. Because the main challenge for the patients using LC-5 is linked to the intake of frequent small doses which can be impractical, the microtablets are paired with a device for their administration. The first device was an electronic dispenser with touch-screen called MyFID, loaded with 750 microtablets in a cassette and capable of notifying the patients with alerts. The new completely mechanic device, OraFID, is pre-filled with 2250 microtablets and enables accurate dosing.
=== Hormone signals === The hormones insulin and cholecystokinin (CCK) are released from the GI tract during food absorption and act to suppress the feeling of hunger. CCK is key in suppressing hunger because of its role in inhibiting neuropeptide Y. Glucagon and epinephrine levels rise during fasting and stimulate hunger. Ghrelin, a hormone produced by the stomach, is an appetite stimulant.
== Applications == Chromatography is used in many fields including the pharmaceutical industry, the food and beverage industry, the chemical industry, forensic science, environment analysis, and hospitals.
Sources: en.wikipedia.org
17α-Alkylation: methyltestosterone, metandienone, fluoxymesterone, oxandrolone, oxymetholone, stanozolol, norethandrolone, ethylestrenol 19-Demethylation: nandrolone, trenbolone, norethandrolone, ethylestrenol, trestolone, dimethandrolone 5α-Reduction: androstanolone, drostanolone, mestanolone, mesterolone, metenolone, oxandrolone, oxymetholone, stanozolol 3β- and/or 17β-esterification: testosterone enanthate, nandrolone decanoate, drostanolone propionate, boldenone undecylenate, trenbolone acetate As well as others such as 1-dehydrogenation (e.g., metandienone, boldenone), 1-substitution (e.g., mesterolone, metenolone), 2-substitution (e.g., drostanolone, oxymetholone, stanozolol), 4-substitution (e.g., clostebol, oxabolone), and various other modifications.
where Da is the symbol for the unit dalton (also called the unified atomic mass unit, symbol u), and e is the elementary charge, which is the unit of electric charge in the system of atomic units. For example, the ion C7H72+ has a mass of 91 Da. Its charge number is +2, and hence its charge is 2e. The ion will be observed at 45.5 Th in a mass spectrum. The thomson allows for negative values for negatively charged ions. For example, the benzoate anion would be observed at −121 Th since the charge is −e.
Avenir Suisse, founded in 1999 by fifteen of the largest Swiss companies. It is supported by over 130 companies to date. DCAF, the Geneva Centre for the Democratic Control of Armed Forces, founded in 2000 to research security sector governance and reform. Gottlieb Duttweiler Institute (GDI), conceived by Migros-founder Gottlieb Duttweiler in 1946. Horasis, which hosts the annual Horasis Global Meeting Liberal Institute, founded in 1979.
Murillo, Mario; Jesus Rey Avirama (September 1, 2003). Colombia and the United States: War, Terrorism and Destabilization. Seven Stories Press. ISBN 1-58322-606-0. Palacios, Marco (1995). Entre la legitimidad y la violencia: Colombia 1875–1994 (in Spanish). Norma. Pardo Rueda, Rafael (2004). La historia de las guerras (in Spanish). Ediciones B-Vergara. ISBN 958-97405-5-3. Hennecke, Angelika (2006). Zwischen Faszination und Gewalt : Kolumbien—unser gemeinsamer Nenner: Reflexionen über das Verhältnis zwischen kultureller Identität, Kommunikation und Medien anhand der diskursanalytischen Untersuchung einer kolumbianischen Werbekampagne (in German). Frankfurt am Main: Peter Lang. ISBN 3-631-54930-X. Pizarro Leongómez, Eduardo (1991). Las Farc: de la autodefensa a la combinación de todas las formas de lucha. Universidad Nacional. Tirado Mejía, Alvaro, ed. (1989). Nueva historia de Colombia. Planeta. Journals and periodicals
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.